Wexford Capital’s Avalo Therapeutics AVTX Stock Holding History

Wexford Capital’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-5	Closed	-$41K	–	208
2020 Q4	$41K	Buy	+5	New	+$34.7K	0.01%	228

Other funds holding AVTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Wexford Capital's AVTX Position: Q1 2021 in Review

Wexford Capital sold out of Avalo Therapeutics (AVTX) in Q1 2021, closing a stake of 5 shares — an estimated $41K sold.

Wexford Capital first reported a position in AVTX in Q4 2020 and held it in 1 quarter. The position peaked at $41K in Q4 2020. 61 funds tracked by Wall St. Rank hold AVTX as of Q1 2021.

Wexford Capital reported no remaining Avalo Therapeutics position as of Q1 2021 after selling out during the quarter.
Wexford Capital sold 5 Avalo Therapeutics shares in Q1 2021, an estimated $41K.
Wexford Capital first reported a position in Avalo Therapeutics in Q4 2020 and held it in 1 quarter.
Wexford Capital's Avalo Therapeutics position peaked at $41K in Q4 2020.
61 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2021.

Based on Wexford Capital's 13F filing for Q1 2021, filed 13 May 2021.